Quantum dots-based quantitative and in situ multiple imaging on Ki67 and cytokeratin to improve Ki67 assessment in breast cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Yuan, Jing Ping ^a   Wang, Lin Wei ^a   Qu, Ai Ping ^b   Chen, Jia Mei ^a   Xiang, Qing Ming ^a   Chen, Chuang ^c   Sun, Sheng Rong ^c   Pang, Dai Wen ^b   Liu, Juan ^b   Li, Yan ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN; QUANTUM DOT; KERATIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; PREDICTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; TISSUE MICROARRAY; BREAST NEOPLASMS; CHEMISTRY; COLOR; GENE EXPRESSION; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; SOFTWARE; STANDARDS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; COLOR; FEMALE; GENE EXPRESSION; HUMANS; KERATINS; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OPTICAL IMAGING; PROGNOSIS; QUANTUM DOTS; ROC CURVE; SOFTWARE; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84928811110     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122734     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64: 52-62. doi: 10.3322/caac.21203 PMID: 24114568
3. Cummings MC, Chambers R, Simpson PT, Lakhani SR. Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology. 2011; 43: 1-8. doi: 10.1097/PAT.0b013e328341e0b5 PMID: 21240058
4. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009; 154: 277-287. doi: 10.1016/j.trsl.2009.09.005 PMID: 19931193
5. Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol. 2012; 23: 2997-3006. doi: 10.1093/annonc/mds586 PMID: 23166150
6. Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS. Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012; 19: 39-53. doi: 10.1097/PAP.0b013e31823fafa0 PMID: 22156833
7. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139: 539-552. doi: 10.1007/s10549-013-2560-8 PMID: 23674192
8. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11: 174-183. doi: 10.1016/S1470-2045(09)70262-1 PMID: 20152769
9. Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012; 61: 1134-1144. doi: 10.1111/j.1365-2559.2012.04329.x PMID: 22963617
10. Reyal F, Hajage D, Savignoni A, Feron JG, Bollet MA, Kirova Y, et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One. 2013; 8: e55901. doi: 10.1371/journal.pone.0055901 PMID: 23526930
11. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 13-20. PMID: 6339421
12. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry. 1991; 12: 42-49. PMID: 1999122
13. Yang XQ, Wang FB, Chen C, Peng CW, Zhang JF, Li Y. High Ki-67 expression is a poor prognostic indicator of 5-year recurrence free survival in patients with invasive breast cancer. Asian Pac J Cancer Prev. 2011; 12: 3101-3105. PMID: 22393997
14. Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, et al. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J. 2013; 19: 22-30. doi: 10.1111/tbj.12059 PMID: 23240985
15. Gong P, Wang Y, Liu G, Zhang J, Wang Z. New insight into Ki67 expression at the invasive front in breast cancer. PLoS One. 2013; 8: e54912. doi: 10.1371/journal.pone.0054912 PMID: 23382998
16. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182: 311-322. PMID: 10653597
17. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103: 1656-1664. doi: 10.1093/jnci/djr393 PMID: 21960707
18. Tawfik O, Kimler BF, Davis M, Stasik C, Lai SM, Mayo MS, et al. Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. Virchows Arch. 2007; 450: 627-636. PMID: 17458558
19. Chen C, Peng J, Sun SR, Peng CW, Li Y, Pang DW. Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Nanomedicine (Lond). 2012; 7: 411-428. doi: 10.2217/nnm.12.9 PMID: 22385199
20. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat. 2009; 114: 277-285. doi: 10.1007/s10549-008-0014-5 PMID: 18418709
21. Hama Y, Koyama Y, Urano Y, Choyke PL, Kobayashi H. Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat. 2007; 103: 23-28. PMID: 17028977
22. Luo Y, Zhang B, Chen M, Jiang T, Zhou D, Huang J, et al. Sensitive and rapid quantification of C-reactive protein using quantum dot-labeled microplate immunoassay. J Transl Med. 2012; 10: 24. doi: 10.1186/1479-5876-10-24 PMID: 22309411
23. Wang LW, Qu AP, Yuan JP, Chen C, Sun SR, Hu MB, et al. Computer-based image studies on tumor nests mathematical features of breast cancer and their clinical prognostic value. PLoS One. 2013; 8: e82314. doi: 10.1371/journal.pone.0082314 PMID: 24349253
24. Tambasco M, Eliasziw M, Magliocco AM. Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival. J Transl Med. 2010; 8: 140. doi: 10.1186/1479-5876-8-140 PMID: 21194459
25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (ed 7). 7th ed. New York: Springer. 2010.
26. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumours of the breast. World Health Organization classification of tumours. 4th ed. Lyon: IARC Press. 2012. PMID: 23006943
27. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28: 2784-2795. doi: 10.1200/JCO.2009.25.6529 PMID: 20404251
28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31: 3997-4013. doi: 10.1200/JCO.2013.50.9984 PMID: 24101045
29. Peng CW, Liu XL, Chen C, Liu X, Yang XQ, Pang DW, et al. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials. 2011; 32: 2907-2917. doi: 10.1016/j.biomaterials.2010.12.053 PMID: 21262536
30. Hu WQ, Fang M, Zhao HL, Yan SG, Yuan JP, Peng CW, et al. Tumor invasion unit in gastric cancer revealed by QDs-based in situ molecular imaging and multispectral analysis. Biomaterials. 2014; 35: 4125-4132. doi: 10.1016/j.biomaterials.2014.01.059 PMID: 24529897
31. Sun JZ, Chen C, Jiang G, Tian WQ, Li Y, Sun SR. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer. Int J Nanomedicine. 2014; 9: 1339-1346. doi: 10.2147/IJN.S58881 PMID: 24648732
32. Voros A, Csorgo E, Nyari T, Cserni G. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology. 2013; 80: 111-118. doi: 10.1159/000343795 PMID: 23258384
33. Zabaglo L, Salter J, Anderson H, Quinn E, Hills M, Detre S, et al. Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol. 2010; 63: 800-804. doi: 10.1136/jcp.2010.077578 PMID: 20671052
34. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10: 7252-7259. PMID: 15534099
35. Wang LW, Yang GF, Chen JM, Yang F, Yuan JP, Sun SR, et al. A clinical database of breast cancer patients reveals distinctive clinico-pathological characteristics: a study from central China. Asian Pac J Cancer Prev. 2014; 15: 1621-1626. PMID: 24641378
36. Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, et al. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat. 2013; 142: 323-339. doi: 10.1007/s10549-013-2748-y PMID: 24194179
37. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011; 22: 500-502. doi: 10.1093/annonc/mdq732 PMID: 21343384
38. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008; 26: 5569-5575. doi: 10.1200/JCO.2008.17.0829 PMID: 18981464
39. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013; 105: 1897-1906. doi: 10.1093/jnci/djt306 PMID: 24203987
40. Romero Q, Bendahl PO, Ferno M, Grabau D, Borgquist S. A novel model for Ki67 assessment in breast cancer. Diagn Pathol. 2014; 9: 118. doi: 10.1186/1746-1596-9-118 PMID: 24934660
41. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012; 7: e37379. doi: 10.1371/journal.pone.0037379 PMID: 22662150
42. Voros A, Csorgo E, Kovari B, Lazar P, Kelemen G, Cserni G. The Use of Digital Images Improves Reproducibility of the Ki-67 Labeling Index as a Proliferation Marker in Breast Cancer. Pathol Oncol Res. 2013.
43. Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 2014; 16: R35. PMID: 24708745
44. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012; 36: 1761-1770. doi: 10.1097/PAS.0b013e318263207c PMID: 23026928
45. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, et al. Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol. 2011; 6 Suppl 1: S7. doi: 10.1186/1746-1596-6-S1-S7 PMID: 21489202
46. Chen C, Sun SR, Gong YP, Qi CB, Peng CW, Yang XQ, et al. Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2. Biomaterials. 2011; 32: 7592-7599. doi: 10.1016/j.biomaterials.2011.06.029 PMID: 21745686
47. Chen C, Xia HS, Gong YP, Peng J, Peng CW, Hu MB, et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials. 2010; 31: 8818-8825. doi: 10.1016/j.biomaterials.2010.07.091 PMID: 20723971